IP Library Granted Patent US 9,452,172
Granted Patent B2
US 9,452,172 · App. 14/240,328 · Granted Sep 27, 2016

(Bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders

Inventors: Avigdor Joshua Scherz (Rehovot, IL); Yoram Salomon (Rehovot, IL); Arie Marcovich (Rehovot, IL); Alexander Brandis (Rehovot, IL); Daniel Wagner (Rehovot, IL)
Assignee: Yeda Research and Development Co. LTD.
A61K31/555A61K31/407A61K41/0071
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,452,172
App. No.
14/240,328
Granted
Sep 27, 2016
Kind
B2
Abstract

An ophthalmic composition is provided, comprising chlorophyll or bacteriochlorophyll compounds for photodynamic treatment (PDT) of diseases, disorders and conditions associated with corneal or scleral anomalies, such as corneal thinning and scleral stretching.

Claims (7)

1. A method of treating keratoconus by photodynamic therapy (PDT), said method comprising the steps of:

(i) administering to an eye of an individual in need thereof an effective amount of Palladium 3 1 -oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 13 1 -(2-sulfoethyl)amide, or a pharmaceutically acceptable salt thereof, and

(ii) irradiating the eye of said individual with light at a red or near infrared (NIR) wavelength.

2. The method according to claim 1 , wherein the pharmaceutically acceptable salt thereof is a potassium salt of Palladium 3 1 -oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 13 1 -(2-sulfoethyl)amide.

3. The method according to claim 2 , wherein the potassium salt of Palladium 3 1 -oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 13 1 -(2-sulfoethyl)amide is Palladium 3 1 -oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 13 1 -(2-sulfoethyl)amide dipotassium salt.

4. The method according to claim 1 , wherein the pharmaceutically acceptable salt thereof is a salt of Palladium 3 1 -oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 13 1 -(2-sulfoethyl) amide with a monovalent alkaline metal or ammonium.

5. The method according to claim 4 , wherein the pharmaceutically acceptable salt thereof is a salt of Palladium 3 1 -oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 13 1 -(2-sulfoethyl) amide with a monovalent alkaline metal selected from the group consisting of potassium, sodium and lithium.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2014
From: SCHERZ, AVIGDOR; SALOMON, YORAM; MARCOVICH, ARIE; BRANDIS, ALEXANDER; WAGNER, DANIEL
To: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Reel/Frame 033356/0763 →
Continuity (2)
Provisional Application 61526414 · Aug 23, 2011
Related Publication 20140378888A1 · Dec 25, 2014